Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
NCT06128733 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1215
Last updated 2026-01-13
Summary
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents.
The study duration will be up to 12 months for all participants.
Conditions
- Meningococcal Immunisation
- Healthy Volunteers
Interventions
- BIOLOGICAL
-
Pentavalent Meningococcal ABCYW vaccine
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
MenACYW conjugate vaccine
Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
Meningococcal group B vaccine
Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
Meningococcal group B vaccine
Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
Meningococcal group B vaccine
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
MenACYW conjugate vaccine
Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
- BIOLOGICAL
-
MenABCYW conjugate vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
Sponsors & Collaborators
-
Sanofi Pasteur, a Sanofi Company
lead INDUSTRY
Principal Investigators
-
Clinical Sciences & Operations · Sanofi
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 10 Years
- Max Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-10-31
- Primary Completion
- 2025-08-27
- Completion
- 2025-08-27
- FDA Drug
- Yes
Countries
- United States
- Puerto Rico
Study Locations
More Related Trials
-
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
NCT05926440 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
NCT01453348 ·Status: COMPLETED ·Phase: PHASE3
-
Novartis Vaccine and Diagnostics Carriage Trial
NCT01214850 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
NCT00518180 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon
NCT03869866 ·Status: COMPLETED ·Phase: PHASE3
-
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS
NCT04258995 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)
NCT04959344 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
NCT05029856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612
NCT00465816 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
NCT00294047 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
NCT03170609 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children
NCT02965404 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT07122986 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
NCT00430534 ·Status: COMPLETED ·Phase: PHASE2
-
ACAM 3000 MVA at Harvard Medical School
NCT00133575 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
NCT06984094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Immunity Persistence Study of Live Attenuated Varicella Vaccine
NCT05095701 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
NCT00258947 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
NCT05933512 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
NCT05188677 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
NCT00053508 ·Status: TERMINATED ·Phase: PHASE2